Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

Background Axitinib is an oral, potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3. We report on data obtained from 18 Japanese patients with advanced solid tumors in two phase I trials that evaluated the safety, pharmacokinetics and antitumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Kiyota, Naomi, Chayahara, Naoko, Suzuki, Akiyuki, Umeyama, Yoshiko, Mukohara, Toru, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348450/
https://www.ncbi.nlm.nih.gov/pubmed/21301929
http://dx.doi.org/10.1007/s10637-011-9637-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348450/
https://www.ncbi.nlm.nih.gov/pubmed/21301929
http://dx.doi.org/10.1007/s10637-011-9637-1

Ejemplares similares